Aptorum Group Limited, a biopharmaceutical company based in London, is focused on the development and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in two segments, Therapeutics and Non-Therapeutics, and has an extensive pipeline of products. Among these are SACT-1, which is being developed for the treatment of neuroblastoma and other cancer types, and SACT-COV19, which aims to treat coronavirus disease. Other products in Aptorum's pipeline include ALS-4, which targets bacterial infections caused by staphylococcus aureus, and ALS-1, which is being developed for the treatment of viral infections caused by influenza virus A. In addition to these products, Aptorum is also developing drugs to treat gram+ve bacterial infections, autoimmune diseases, and metabolic disorders, among others. The company's pipeline products are designed to enable the systematic screening of existing drug molecules and microbiome-based research platforms, facilitating the discovery of new therapeutic assets. Aptorum is also focused on diagnostic and therapeutic projects in areas including neurology, gastroenterology, and women's health. The company even operates a medical clinic. Aptorum Group Limited was incorporated in 2010, and its activities are of great interest to investors in the biopharmaceutical industry. As the company continues to develop its pipeline of products, it is worth watching closely to see what new treatments it may bring to market in the years ahead.